Pipeline & Medicines Explore the Science of Possibility View Vertex Research Giving BackLearn more about our STEM Program, Volunteer Efforts, Grants and Funding./giving-back Recent UpdatesFDA Approves SYMDEKOExpanded EU Approval for ORKAMBIKALYDECO Approved for Additional Mutations The Stories Behind Vertex: Giving Back $1 Million In: The Power of a Double Donation Science Paul Negulescu Awarded the Warren Alpert Foundation Prize for Contributions to CF Science Science Health Canada Approves SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) Science FDA Approves SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) We Are Vertex Fueling the Future of Our Innovation Ecosystem Science Vertex Initiates Second Phase 3 VX-659 Triple Combination Study in Certain People with Cystic Fibrosis × All in for CF Meet All in for CF Scholarship Recipient Jenny Livingston × We Are Vertex Ian Pettigrew’s Authentic Portraits Reveal the Passion and Commitment of the People Behind Our Medicines All in for CF 11-Year-Old with Cystic Fibrosis Joins Team Sports for the First Time Through the Vertex Team IMPACT CF Project We Are Vertex Voices From Research: Hear Stories From Our Scientists Explore More Stories @vertexpharma
Science Vertex Initiates Second Phase 3 VX-659 Triple Combination Study in Certain People with Cystic Fibrosis
× We Are Vertex Ian Pettigrew’s Authentic Portraits Reveal the Passion and Commitment of the People Behind Our Medicines
All in for CF 11-Year-Old with Cystic Fibrosis Joins Team Sports for the First Time Through the Vertex Team IMPACT CF Project
